1734 — Sinphar Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapNeutral

Annual cashflow statement for Sinphar Pharmaceutical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-118	-185	245	306	307
Depreciation
Amortisation
Non-Cash Items	18.7	25.1	23.3	-42.4	22.3
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-5	25.5	-110	-210	6.78
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	146	136	425	296	594
Capital Expenditures	-158	-161	-153	-301	-257
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-7.91	-44.2	29.2	-33.6	-134
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-166	-206	-124	-335	-391
Financing Cash Flow Items	92.6	160	-10.7	15.2	1
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	319	123	-263	-121	-209
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	303	51	42.8	-163	1.18